Comprehensive Metabolic Panel Testing Market Size, Share & Trends Analysis Report By Analytes (K+, Na+, Cl-, CO2, Glucose), By Disease, By End-use (Laboratory, PoC), By Region, And Segment Forecasts, 2023 - 2030

Comprehensive Metabolic Panel Testing Market Size & Trends

The global comprehensive metabolic panel testing market size was estimated at USD 10.19 billion in 2022 and is expected to grow a compound annual growth rate (CAGR) of 9.1% from 2023 to 2030. Factors such as the rising prevalence of chronic diseases and emphasis on early diagnosis and treatment are expected to drive the demand for CMP testing. The high prevalence of lifestyle-associated diseases, such as obesity, smoking, unhealthy eating habits, and lack of physical activity, are among the factors responsible for increasing the incidence of chronic diseases. The rise in the geriatric population is driving the market as they are more prone to diabetes and cardiovascular diseases. According to World Health Organization (WHO), over 1 billion people are over 60 years and are estimated to reach 1.4 billion by 2030.

Diabetes is one of the fastest-growing diseases in the world, widening the patient pool for point-of-Care (PoC) CMP testing. The increasing prevalence of diabetes and cardiovascular, and other target diseases is anticipated to boost the demand for CMP testing over the forecast period. Cardiovascular diseases are fatal and are considered the leading cause of death worldwide. According to WHO, cardiovascular diseases (CVDs) cause 17.9 million deaths annually.

The healthcare industry largely depends on regulatory frameworks established by organizations such as the U.S. Food and Drugs Administration (FDA) and the European Medicines Agency (EMA). Regulatory bodies such as Clinical Laboratory Improvement Amendments (CLIA) regulate the approval of these tests, and government bodies set the fee waiver and the reimbursement for Medicare and Medicaid. The FDA has control over the Laboratory-Developed Tests (LDTs) which refer to in-house clinical laboratories developing tests, delivering efficient and rapid results. For instance, in 2020, the EU4Health program was initiated, health is considered an investment, and the EU4Health program, with a budget of over USD 5.8 billion for 2021-27, is a significant financial support from the EU in the health sector. This program reflects the EU's commitment to prioritizing public health and plays a crucial role in moving toward establishing a European Health Union.

Reimbursement and regulatory bodies in Europe impose stringent laws. Most European manufacturers set the pricing based on the Return on Investment (RoI) and follow value-based pricing. There is an oversupply of testing products that are redundant and a large number of products with similar indications. However, this led to lower pricing, faster processing time, and wider availability of the products.

The introduction of innovative solutions for enhancing efficiency and minimizing errors is expected to boost the CMP testing market growth over the forecast period. Integrated workflow management systems and database management tools are gaining importance, with companies processing several thousand samples per year. Development and execution of various bioinformatics and data management solutions, coupled with the emergence of automated laboratory systems, indicate a prosperous future for the market.

The COVID-19 pandemic had a significant impact on the comprehensive metabolic panel testing market. Numerous tests have been conducted on blood as a result of the rise in COVID-19; doctors were ordering CMP tests for COVID positive patients to check complete blood count, d-dimer protein, and prothrombin time, and this increase in testing has driven the market for complete metabolic panels overall. According to WHO, 767,984,989 confirmed COVID cases have been registered.

Analytes Insights

On the basis of analytes, the market of comprehensive metabolic panel testing is segmented into K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, total protein, ALP, ALT, AST, total bilirubin. The glucose segment accounted for the highest revenue share of 11.08% in 2022. Blood sugar is another name for glucose. Blood glucose may be measured with a CMP. A form of sugar called glucose gives your body and brain energy. A high fasting blood glucose level is frequently an indication of Type 2 diabetes. According to International Diabetes Federation (IDF), over 540 million people are suffering from diabetes worldwide, and by 2045 the numbers are expected to cross 780 million marks.

The K+ segment is expected to grow at the fastest CAGR of 9.6% over the forecast period. The CMP test helps physicians detect or monitor renal illness, the most common cause of excessive potassium levels. It also provides information on the body's fluid balance, electrolytes such as potassium levels, and how well the liver and kidneys are functioning. When a patient exhibits symptoms of high blood pressure or cardiac issues, these tests are prescribed. In the U.S., chronic kidney disease (CKD) has developed into a public health issue. The CDC estimates that 15% of U.S. adults, or around 37 million people, have CKD as of 2019. People with CKD are more likely to be over 65 (38%) than between 45 and 64 (13%) or between 18 and 44 (7%). Compared to males (12%), women (15%) have a higher prevalence of CKD. One of the main drivers of the growth of the CMP testing market is the increase in chronic illnesses, including renal, diabetes, and liver disorders.

Disease Insights

On the basis of disease, the market of comprehensive metabolic panel testing is segmented into kidney diseases, liver diseases, diabetes, and others. The kidney diseases segment accounted for the largest revenue share of 32.71% in 2022, and the segment is driven by a high disease prevalence and maximum utilization of analytes. Renal anomalies could arise from other comorbidities, such as diabetes and high blood pressure. Nearly 50% of patients had a history of cardiovascular disease or diabetes. Lack of early symptoms poses a challenge to the early diagnosis of the disease.

The diabetes segment is expected to grow at the fastest CAGR of 9.9% during the forecast period. Nearly 50% of diabetics remain undiagnosed, presenting a lucrative opportunity for growth for the comprehensive metabolic panel testing market. Abbott partnered with important health tech companies BeatO, PharmEasy, GOQii, and Sugar.fit, 1MG, Zyla Health, Fitterfly, and HealthifyMe in February 2022 to usher in a new era of comprehensive diabetes management treatment. With the help of these partnerships, Abbott hopes to cure 8 million diabetics.

End-use Insights

On the basis of end-use the market of comprehensive metabolic panel testing is segmented into laboratories and PoC. The laboratories segment accounted for the highest revenue share of 59.97% in 2022, driven by easy availability, high market penetration, increased usage, and clinically significant results. Some laboratories may be in/and affiliated with hospitals, blood banks, and specialized diagnostic centers. Among laboratories, hospital wards had the biggest revenue share of 31.20%. Furthermore, the extensive presence of ancillary support - in terms of manpower and infrastructure - is a key propeller for market growth.

The PoC segment is expected to grow at the fastest CAGR of 9.8% over the forecast period. The PoC CMP tests are driven by their ease of operation, portability, speed of results, and lesser requirement of the sample. Among PoC, telemedicine is expected to grow at a fastest CAGR of 10.1% owing to digitization and ease of availability.  Abbott has provided Henry Schein Medical with two complete diagnostic solutions that comply with Clinical Laboratory Improvement Amendments (CLIA) and allows to test, diagnose, and treat patients in the same visit.

Regional Insights

North America dominated the comprehensive metabolic pane testing market and accounted for the largest revenue share of 45.70% in 2022, owing to strong commercial performances of CMP diagnostics in the U.S. High disease burden, rising consumer awareness, proactive government measures, technological advancements, and improvements in healthcare infrastructure are some of the major contributors of market growth. Furthermore, the presence of key players is projected to bode well for the demand for CMP testing. According to Nova Biomedical, the FDA granted approval for the use of the Stat Profile Prime + critical care blood analyzer at point-of-care in April 2020. The Prime Plus analyzer can conduct 19 critical care tests, covering hematology, blood gases, metabolites, electrolytes, and co-oximetry. These sensor assays are maintenance-free, providing healthcare professionals with rapid and comprehensive diagnostic results, including a complete metabolic panel.

Asia Pacific is expected to grow at the highest CAGR of 11.7% over the forecast period, driven by improvements in healthcare infrastructure, a rise in the number of older people, who are more susceptible to chronic illnesses, growth in consumer awareness, a rise in disposable income, and overall economic development. According to Asian Development Bank, in Asia and the Pacific, one in four persons will be older than 60 by 2050. Between 2010 and 2050, the region's elderly population is projected to quadruple. The market in emerging countries such as China, India, and South Korea is expected to witness rapid growth in demand for CMP testing during the forecast period.

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach. For instance, Sonic Healthcare acquired ProPath in Dec 2021 for an undisclosed amount and Aurora Diagnostics in Dec 2018 for USD 540 million. ProPath regularly diagnoses patients from 45 states and several other nations under the direction of a group of top-tier medical professionals and researchers. The following are some of the major participants in the comprehensive metabolic panel testing market:

• Abbott

• Quest Diagnostics

• Laboratory Corporation of America Holdings Limited

• Sonic Healthcare

• Unipath

• SYNLAB International GmbH

• ARUP Laboratories

• Genoptix Inc.

• Nova Medical

Comprehensive Metabolic Panel Testing Market Report Scope

Global Comprehensive Metabolic Panel Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global comprehensive metabolic panel testing market on the basis of disease, analytes, end-use, and region:

• Analytes Outlook (Revenue, USD Million, 2018 - 2030)

  • K+

  • Na+

  • Cl-

  • CO2

  • Glucose

  • BUN

  • Creatinine

  • Ca++

  • Albumin

  • Total Protein

  • ALP

  • ALT

  • AST

  • Total Bilirubin

• Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Kidney Diseases

  • Liver Diseases

  • Diabetes

  • Others

• End-use Outlook (Revenue,  USD Million, 2018 - 2030)

  • Laboratories

    • Emergency Departments

    • Hospital Wards

    • Primary Care

    • Pharmacy

    • Telemedicine

  • PoC

    • Emergency Departments

    • Hospital Wards

    • Primary Care

    • Pharmacy

    • Telemedicine

  • PoC (Instruments)

    • Piccolo Xpress

    • Skyla-HB1

    • DRI-CHEM NX500

    • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait